The androgen receptor gene GGN microsatellite and prostate cancer risk

被引:0
|
作者
Platz, EA
Giovannucci, E
Dahl, DM
Krithivas, K
Hennekens, CH
Brown, M
Stampfer, MJ
Kantoff, PW
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Dept Med, Div Urol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dept Med, Div Prevent Med, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA
[7] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Neoplast Dis Mechanisms, Boston, MA 02115 USA
[8] Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The androgen receptor (AR) gene contains a polymorphic GGN microsatellite in exon 1, which encodes polyglycine in the amino terminus of the AR. Previous work has shown that a polymorphic region of CAG repeats also in exon 1 is inversely related to the ability of the AR to transactivate other genes and to prostate cancer risk. We investigated whether AR gene GGN repeat length is related to prostate cancer in a nested study of 582 cases and 794 controls matched on age and smoking status in the Physicians' Health Study. DNA was prepared from archived blood. Using PCR, the region surrounding the GGN repeat was amplified. Fluorescence-labeled primers were used such that the fragment produced could be sized using polyacrylamide gels and Genescan software. We estimated odds ratios and 95% confidence intervals from logistic models controlling for the matching variables for the relation between GGN repeat length and total prostate cancer and by stage/grade and by age at diagnosis. Among controls, the most frequent GGN repeat lengths were 23 (53.5%) and 24 (34.0%), with a range of 10-29, There was no statistically significant difference in the mean GGN repeat length between cases (23.13) and controls (23.05), However, cases had a narrower spread of repeats lengths (parametric test, P = 0.03; nonparametric test, P = 0.07) than controls, with fewer extreme lengths in either direction. The risk of total prostate cancer was slightly increased for a GGN repeat length of 23 compared to all others (odds ratio, 1.20; 95% confidence interval 0.97-1.49); risk did not vary by tumor stage/grade. For every one repeat deviation in either direction from 23, the risk of prostate cancer decreased by 8% (P = 0.04), Although the AR gene GGN repeat probably plays only a modest role in prostate cancer, the observed relation of this repeat with prostate cancer risk supports the evaluation of the effect of GGN repeat length on AR transactivation.
引用
收藏
页码:379 / 384
页数:6
相关论文
共 50 条
  • [41] Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men
    Panz, VR
    Joffe, BI
    Spitz, I
    Lindenberg, T
    Farkas, A
    Haffejee, M
    ENDOCRINE, 2001, 15 (02) : 213 - 216
  • [42] Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk
    Bao-li Chang
    Siqun L. Zheng
    Gregory A. Hawkins
    Sarah D. Isaacs
    Kathy E. Wiley
    Aubrey Turner
    John D. Carpten
    Eugene R. Bleecker
    Patrick C. Walsh
    Jeffrey M. Trent
    Deborah A. Meyers
    William B. Isaacs
    Jianfeng Xu
    Human Genetics, 2002, 110 : 122 - 129
  • [43] Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men
    Vanessa R. Panz
    Barry I. Joffe
    Mohammed Haffejee
    Irving Spitz
    Tzina Lindenberg
    Amicur Farkas
    Endocrine, 2001, 15 : 213 - 216
  • [44] Androgen receptor and prostate cancer
    Richter, E.
    Srivastava, S.
    Dobi, A.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2007, 10 (02) : 114 - 118
  • [45] Androgen receptor and prostate cancer
    Livermore, Karen E.
    Munkley, Jennifer
    Elliot, David J.
    AIMS MOLECULAR SCIENCE, 2016, 3 (02): : 280 - 299
  • [46] The androgen receptor in prostate cancer
    Trapman, J
    Brinkmann, AO
    PATHOLOGY RESEARCH AND PRACTICE, 1996, 192 (07) : 752 - 760
  • [47] Androgen receptor in prostate cancer
    Heinlein, CA
    Chang, CS
    ENDOCRINE REVIEWS, 2004, 25 (02) : 276 - 308
  • [48] Androgen receptor and prostate cancer
    E Richter
    S Srivastava
    A Dobi
    Prostate Cancer and Prostatic Diseases, 2007, 10 : 114 - 118
  • [49] Androgen receptor genotypes and risk of human prostate cancer.
    Kaartinen, K
    Schleutker, J
    Matikainen, M
    Tammela, T
    Visakorpi, T
    Kallioniemi, OP
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A362 - A362
  • [50] The androgen/androgen receptor axis in prostate cancer
    Bluemn, Eric G.
    Nelson, Peter S.
    CURRENT OPINION IN ONCOLOGY, 2012, 24 (03) : 251 - 257